Q-omics provides the consensus-scored SCARNA6 profile across patient tissues and cancer cell-line models. SCARNA6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCARNA6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SCARNA6 RNA expression shows 16,587 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where SCARNA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARNA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARNA6 survival associations across molecular data types. SCARNA6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARNA6 RNA expression–survival associations across cancer types. High SCARNA6 expression shows unfavorable associations in UVM, PAAD, LIHC and ACC, but favorable associations in BRCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SCARNA6 RNA expression.
This table summarizes SCARNA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCARNA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARNA6 shows lower tumor expression in THCA and higher tumor expression in KIRC, STAD, COAD, KIRP and HNSC. The KIRC box plot shows higher SCARNA6 RNA expression in tumor versus normal tissue (log2 FC = +0.559, t-test p < 0.001).
This table shows molecular features associated with SCARNA6 in patient tissues and cancer cell lines. In patient samples, SCARNA6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
